Biomea Fusion, Inc.

NASDAQ:BMEA

Biotechnology

Healthcare
$0.74 -2.50%

-$0.03 today

Market cap
$53.18M
Beta
-0.33
P/E (TTM)
-1.9
EPS (TTM)
-$0.62
52W Low $0.87High $2.99

Volume 3.50M

Average 1.52M

BMEA Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Biomea Fusion, Inc.NASDAQ: BMEA

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns positive

Q1 FY2026 accounts payables was $1.38M, compared with -$5.22M a year earlier. Trailing-twelve-month accounts payables was -$3.1M.

Context

  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $1.38M or moves back toward the trailing-twelve-month quarterly average of -$775K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.38M+143.5% QoQ
Last fiscal yearDec 2025
-$9.7M-259.3% YoY
LTMMar 2026
-$3.1M-201.8% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+126.4%——
1 year-259.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(9.7M) USD
Year-over-year change
-259.3%

Accounts Payables vs competitors

How BMEA compares with its peers on the latest reported figures

  • BMEA's LTM Mar 2026 accounts payables of $3.1M is the 3rd largest of the 9 companies compared; the peer median is $716K.
  • Its year-over-year change of -201.8% is the 6th highest of 8, against a peer median of -157.4%.
BMEA Competitors Peer median
Accounts Payables for BMEA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMUXImmunic, Inc.LTM Mar 2026$4.41M +702.6%+15.7%—
STROSutro Biopharma, Inc.LTM Mar 2026$3.13M -534.1%+26.3%3.1%
BMEABiomea Fusion, Inc.LTM Mar 2026$3.1M -201.8%——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$1.96M -171.6%+106.5%—
CBUSCibus, Inc.LTM Mar 2026$1.56M -1070.8%—36.5%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$1.01M -157.4%——
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$421K ——10.7%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$233K -91.2%-54.6%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$170K -60.6%——
Peer median (excluding BMEA) $716K-157.4%+21.0%10.7%

Competitors are the stored peer set for BMEA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(41.57M)(81.83M)(117.26M)(138.43M)(61.8M)
Depreciation & Amortization249K691K1.52M1.75M1.41M
Deferred Income Tax00000
Stock-Based Compensation6.23M10.34M14.13M19.09M9.52M
Change in Working Capital(1.57M)7.67M2.33M(5.15M)(3.7M)
Accounts Receivables00000
Inventory00000
Accounts Payables640K2.96M2.56M6.09M(9.7M)
Other Working Capital(2.21M)4.71M(232K)(11.24M)6M
Other Non-Cash Items1.22M715K2.69M2.84M(15.81M)
Operating Cash Flow(35.44M)(62.42M)(96.59M)(119.89M)(70.37M)
Capital Expenditures(3.17M)(1.03M)(3.37M)(362K)0
Acquisitions (Net)00000
Purchases of Investments(38.49M)0000
Sales of Investments8.31M28.37M1.15M00
Other Investing Activities00000
Investing Cash Flow(33.35M)27.34M(2.22M)(362K)0
Debt Repayment(36K)0000
Common Stock Issued153.22M0161.8M1.67M67.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities01.24M2M00
Financing Cash Flow153.19M1.24M163.8M1.67M67.9M
Effect of Forex Changes(351K)0000
Net Change in Cash84.04M(33.84M)64.99M(118.59M)(2.47M)
Free Cash Flow(38.61M)(63.45M)(99.96M)(120.26M)(70.37M)

Biomea Fusion, Inc.

NASDAQ:BMEA

Intrinsic Alpha fair value

Locked

Current Price

$0.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.